CURRICULUM VITAE
BIOGRAPHICAL INFORMATION
Sulaiman Ali Said Al-Hashmi
Sultan Qaboos University
College of Medicine and Health Sciences
Department of Genetics
P.O. Box 35, Al-Khod 123, Sultanate of Oman
Mobile: +968 94103446
Work: +968 2414 3525
E-mail: ssshashmi2009@hotmail.com
LANGUAGE
Arabic and English
EDUCATION, DEGREES & CERTIFICATES GRANTED
2007 to 2011: Ph.D. degree in Medical Sciences, Karolinska Institute, Sweden
Topic: Complication of stem cell transplantation: studies in mouse model
1999 to 2000: Master in Sciences, University of Bristol, United Kingdom
Topic: Transplantation & Transfusion sciences
1989 to 1994: Bachelor of Sciences, Department of Chemistry, Sultan Qaboos University (SQU), Sultanate of Oman
Topic: Chemistry (major; organic chemistry)
LEADERSHIP & HOSPITAL ACTIVITIES
2003 to 2006: In charge of the National Tissue Typing laboratory (NTTL), SQU Hospital (SQUH), Sultanate of Oman. Main duties include:
· Verification of laboratory tests
· Authorization of patients reports
· Evaluation of the laboratory budget
· Improving the laboratory standards
· Supervising the laboratory staff
· Teaching students and communication with other hospitals
2011 to date: Co-supervision of the NTTL, SQUH, Sultanate of Oman. Main duties include:
· Establishment of the research facilities
· Planning and conducting biomedical research
· Teaching & supervising of medical students
LABORATORY & COMPUTER SKILLS
Having experience in:
· Cell culture, cytotoxicity assay & flow cytometry
· Molecular techniques & Western blotting
· Wire myography technique
· Mouse model techniques (I.P, I.V. & S.C. injections, blood sampling, dissection & tissues harvest, & preparation of cell suspension from bone marrow, spleen, thymus, liver, lung, Peyer’s patches & lymph nodes)
· Microsoft office programs
· Analysis programs such as SPSS, Cell Quist & Graph Pad Prism
TEACHING & TRAINEES SUPERVISION
2012 to date: Developer and coordinator of Cell Biology Course for biomedical scientists, second year
2011 to date: Lecturer, HLA typing, stem cell biology and cell therapy, hematopoiesis, bioethics and lab techniques and application in cell biology
2003 to date: Trained and supervised biomedical scientists, medical students, biotechnologists & research assistants
RESEARCH INTEREST & ACTIVITIES
· Hematopoietic stem cell biology and cell therapy
· Cancer cells biology and cancer treatment
· Mesenchymal stem cell therapy
· Regenerative medicine
My special interest is in stem cell biology, transplantation immunology, cancer and regenerative medicine. I started a research program at Lund University Stem Cell Center (SCC) for 14 months, focusing on stem cell biology. I worked on stem cell differentiation and proliferation using different techniques, including cell culture, viral and vector transduction, flow cytometry, cell sorting and cell staining methods. After that I moved to Karolinska Institute to perform my PhD degree in stem cell transplantation and its consequence complications using animal models. I have several publications as fist or co-author.
Currently I am part of few studies as a principal investigator or as a co-investigator. One of the studies is to assess the toxicity of anti-cancer drugs that are also in use as a preparative conditioning regimen for stem cell transplantation (SCT). The other part of my research is the use of mesenchymal stem cell (MSC) to treat the complication resulting from drug toxicity and SCT in mouse model. We harvest the MSC from bone marrow, adipose tissue and fetal membrane. With strong international collaboration, I have ambitious to build up a center for stem cell therapy and regenerative medicine.
MEMBERSHIP IN PROFESSIONAL & SCIENTIFIC SOCIETIES
2008 to date: International Society for Stem Cell Research (ISSCR)
RESEARCH GRANT
1. Source: The research Council, Oman
Project title: Exploration of new Acetyl 11-Keto-β Boswellic acid (AKBA)Derivativesas Tumor sensitizing agents
Role: Co-investigator
Amount: 330,000 OMR
Term: 2015-2017
2. Source: SQU, Internal Grant
Project title: Mesenchymal stem cells as a tool to repair vascular damage following chemotherapy conditioning regimen
Role: Principle investigator
Amount: 24,000 OMR
Term: 2013-2014
3. Source: His Majesty GRANT (HM grant)
Project title: Identification of novel therapeutic targets for inflammatory-associated human disorders
Role: Co-principal Investigator
Amount: 92,000 OMR
Term: 2013-2015
4. Source: The research Council, Oman
Project title: Testing the Breg cell hypothesis in sickle cell disease: implication for pathogenesis
Role: Co- investigator
Amount: 83.520 OMR
Term: 2013-2015
5. Source: To be submitted to one of the grant funders
Project title: Use of mesenchymal stem cells in prevention of post- transplantation complications
Role: Principle investigator
Term: Under preparation
APPOINTMENTS
2012 to date: Associate Researcher (A), Department of Genetics, College of Medicine and Health Sciences (CM &HS), SQU, Sultanate of Oman
2006 to 2011: Associate Researcher (B), Department of Genetics, CM & HS, SQU, Sultanate of Oman
2005 to 2006: Assistance Researcher (A), Department of Genetics, CM & HS, SQU, Sultanate of Oman
2001 to 2005: Senior Technician, Department of Surgery, CM & HS, SQU, Sultanate of Oman
1994 to 1999: Technician, Department of Surgery, CM & HS, SQU, Sultanate of Oman
1995: Three months training at the Department of Hematology CM & HS, SQU, Sultanate of Oman
TRAINING PROGRAMS
19 – 23 October, 2009: Workshop; Photomicrography, Karolinska Institute, Sweden
Feb 2006 – March 2007: Researcher; Stem Cell Center, Lund University, Sweden
Aug – Nov 2003: Training; University of Toronto and McMaster University, Canada
1998: Training; Cambridge University teaching hospital, Cambridge, United Kingdom
1997: Training; Hematology & Biochemistry, CM & HS, SQU, Sultanate of Oman
1996: Workshop; Use and Application of Scientific Instrumentation: Principles and Practice, CM & HS, SQU, Sultanate of Oman
CONFERENCE ATTENDANCE
21- 22 April, 2005: 1st Roche Middle East Transplant Congress, Cairo, Egypt
1 – 4 December 2004: Transplant Asia 2004, Singapore
2003 & 2004: Arab-Lab Instrumentation Exhibition, Dubai, UAE
21 – 24 October, 2002: VIII International Congress of the Middle East Society for Organ Transplantation, Muscat, Sultanate of Oman
1998: European International Conference for Organ Transplantation, London, UK
PUBLICATIONS IN PEER REVIEWED JOURNALS
1. Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R, Lundahl J, Hassan M, Moshfegh A. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS One. 2013;8 (4):e60367.
2. Sadeghi B, Al-Chaqmaqchi H, Al-Hashmi S, Brodin D, Hassan Z, Abedi-Valugerdi M, Moshfegh A, Hassan M. Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target? Bone Marrow Transplant. 2013; 48:284-293.
3. Al Hashmi S, Sadeghi B, Hassan Z, Abedi-Valugerdi M, Lindskog M, Hassan M. Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion. Bone Marrow Transplant. 2012; 48:843-848.
4. Al-Hashmi S, Boels PJ, Zadjali F, Sadeghi B, Sällström J, Hultenby K, Hassan Z, Arner A, Hassan M. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One. 2012;7(1):e30897.
5. Al-Hashmi S, Hassan Z, Sadeghi B, Rozell B, Hassan M. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. Int J Clin Exp Pathol. 2011; 4:596-605.
6. Sadeghi B, Hägglund H, Remberger M, Al-Hashmi S, Hassan Z, Abedi-Valugerdi M, Hassan M. Glucosamine Activates T Lymphocytes in Healthy Individuals and may Induce GVHD/GVL in Stem Cell Transplanted Recipients. The Open Transplant. J. 2011; 5: 1-7.
7. Sadeghi B, Al-Hashmi S, Hassan Z, Rozell B, Concha H, Lundmark C, Grönvik KO, Abedi-Valugerdi M, Hassan M. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin Dev Immunol. 2010;2010:142943.
8. Al-Mamari F, Al-Shirawi A, Banodkar D, Al-Hashmi S, Al-Yahyaae F, Varghese M, Raeburn J. HLA Antigens in Omani Psoriasis Vulgaris Patients. Oman Med J. 2009; 24:27-29.
9. Said R, Sadeghi B, Al-Hashemi S , Abdel-Rehim M, Hassan M, Hassan Z. Cyclophosphamide Pharmacokinetics in Mice: A Comparison Between Retro Orbital Sampling Versus Serial Tail Vein Bleeding. The Open Pharmacol. J. 2007; 1:22-27.
10. Månsson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S, Al-Hashmi S, Liuba K, Thorén L, Adolfsson J, Buza-Vidas N, Qian H, Soneji S, Enver T, Sigvardsson M, Jacobsen SE. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity. 2007; 26:407-419.
12. White AG, Bogh J, Leheny W, Kuchipudi P, Varghese M, al Riyami H, Al-Hashmi S, Daar AS. HLA antigens in Omanis with blinding trachoma: markers for disease susceptibility and resistance. Br J Ophthalmol. 1997; 81:431-434.
13. White AG, Leheny W, Kuchipudi P, Varghese M, Al Riyami H, Al Hashmi S, Daar AS. Histocompatibility antigens in Omanis: Comparison with other Gulf populations and implications for disease association. Ann Saudi Med. 1999; 19:193-196.
ABSTRACTS AND CONFERENCE PRESENTATIONS (PEER REVIEWED)
1. Oral presentation
Mesenchymal Stem Cells to Repair Vascular Damage After Chemotherapy: Past, Present
and Future. 3rd International Conference and Exhibition on Cell & Gene Therapy, October 27-29, 2014, Las Vegas, USA.
2. Abstract
Al-Hashmi S, Sadeghi B, Hassan Z, Lindskog M, Hassan M. Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion”, American Society of Hematology (ASH), Atlanta, USA, 8 – 11 December 2012.
3. Abstract
Al-Hashmi S, Sadeghi B, Hassan Z, Lindskog M, Hassan M. The effect of omega-3 as a dietary supplement in mouse model of stem cell transplantation. Haematologica 2009; 94[suppl.2]:472 abs.
4. Abstract
Sadeghi B, Al-Hashmi S, Hassan Z, Rozell B, Abedi-Valugerdi M, HassanM. Immunopathology of ATG prior to bone marrow transplantation in mouse model. Haematologica 2009; 94[suppl.2]:463 abs. 1144
5. Abstract
Sadeghi B, Al-Hashmi S, Hassan Z, Lundmark C, Concha H, Rozell B, Abedi-Valugerdi M, Hassan M. Dynamics of donor T cell activation during early phase of graft versus host disease (GVHD): donor antigen presenting cells can activate allogeneic T cells. Haematologica 2009; 94, 461-461
6. Abstract
Asktorab H, Brim H, Al-Riyami M, Date A, Al-Mawaly K, Kashoub M, Al-Mjeni R, Smoot DT, Al-mandhari M, Al-Hashemi S, Ganguli SS, Raeburn S. Sporadic Colon Cancer: Mismatch Repair and Microsatellite Instability Genes in Omani Subjects. Histophology Microsatellite Instability and Mismatch Repair Status In Sporadic Colorectal Cancer Patient In Oman. 96th Annual Meeting of the American Association of Cancer Research, Washington DC, May 2005.